Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) are up-regulated in hepatocellular carcinoma (HCC). To investigate the levels of COX-2 and VEGF expression in chronic hepatitis (CH), cirrhosis,and HCC. Methods: The immunohistochemical expressions of COX-2 and VEGF were evaluated in tissues from patients with CH (n =95), cirrhosis (n =38), low-grade HCC (LG-HCC; n =6), and high-grade HCC (HG-HCC; n =29). Results: The COX-2 expression scores in CH, cirrhosis, LG-HCC, and HG-HCC were 3.3±1.9 (mean±SD), 4.2±1.7, 5.5±1.0,and 3.4±2.4, respectively (CH vs. cirrhosis, P =0.016; CH vs. LG-HCC, P =0.008; LG-HCC vs. HG-HCC, P =0.004), and the corresponding VEGF expression scores were 0.9±0.8, 1.5±0.7, 1.8±0.9, and 1.6±1.1 (CH vs. cirrhosis, P<0.001; CH vs. LGHCC,P=0.011; LG-HCC vs. HG-HCC, P=0.075). Both factors were correlated with the fibrosis stage in CH and cirrhosis (COX-2:r=0.427, P<0.001; VEGF: r=0.491, P<0.001). There was a significant correlation between COX-2 and VEGF in all of the tissue samples (r=0.648, P<0.001), and between high COX-2 and VEGF expression scores and survival (COX-2: P=0.001; VEGF:P<0.001). Conclusions: The expressions of both COX-2 and VEGF are significantly higher in cirrhosis and LG-HCC than in CH. High COX-2 and high VEGF expressions are associated with a high survival rate. (Clin Mol Hepatol 2012;18:287-294)
Abstract
Background/Aims: Cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) are up-regulated in hepatocellular carcinoma (HCC). To investigate the levels of COX-2 and VEGF expression in chronic hepatitis (CH), cirrhosis,and HCC. Methods: The immunohistochemical expressions of COX-2 and VEGF were evaluated in tissues from patients with CH (n =95), cirrhosis (n =38), low-grade HCC (LG-HCC; n =6), and high-grade HCC (HG-HCC; n =29). Results: The COX-2 expression scores in CH, cirrhosis, LG-HCC, and HG-HCC were 3.3±1.9 (mean±SD), 4.2±1.7, 5.5±1.0,and 3.4±2.4, respectively (CH vs. cirrhosis, P =0.016; CH vs. LG-HCC, P =0.008; LG-HCC vs. HG-HCC, P =0.004), and the corresponding VEGF expression scores were 0.9±0.8, 1.5±0.7, 1.8±0.9, and 1.6±1.1 (CH vs. cirrhosis, P<0.001; CH vs. LGHCC,P=0.011; LG-HCC vs. HG-HCC, P=0.075). Both factors were correlated with the fibrosis stage in CH and cirrhosis (COX-2:r=0.427, P<0.001; VEGF: r=0.491, P<0.001). There was a significant correlation between COX-2 and VEGF in all of the tissue samples (r=0.648, P<0.001), and between high COX-2 and VEGF expression scores and survival (COX-2: P=0.001; VEGF:P<0.001). Conclusions: The expressions of both COX-2 and VEGF are significantly higher in cirrhosis and LG-HCC than in CH. High COX-2 and high VEGF expressions are associated with a high survival rate. (Clin Mol Hepatol 2012;18:287-294)
참고문헌 (23)
- Verburg KM, "Cox-2-specific inhibitors: definition of a new therapeutic concept", Am J Ther, 8, pp.49~64 (2001)
- Wu T, "Cyclooxygenase-2 in hepatocellular carcinoma", Cancer Treat Rev, 32, pp.28~44 (2006)
- Ishak K, "Histological grading and staging of chronic hepatitis", J Hepatol, 22, pp.696~699 (1995)
- Qiu DK, "Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma", World J Gastroenterol, 8, pp.815~817 (2002)
- Chen ZB, "The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus", Med Oncol, 26, pp.365~371 (2009)
- Morinaga S, "Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma", J Gastroenterol Hepatol, 17, pp.1110~1116 (2002)
- Pazirandeh S, "Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States", Dig Dis Sci, 52, pp.220~227 (2007)
- Koga H, "Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation", Hepatology, 29, pp.688~696 (1999)
- Mohammed NA, "Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis", J Clin Pathol, 57, pp.350~354 (2004)
- Yu J, "Expression of a cyclo-oxygenase-2 transgene in murine liver causes hepatitis", Gut, 56, pp.991~999 (2007)
- Mallat A, "Platelet-derived growth factor-BB and thrombin generate positive and negative signals for human hepatic stellate cell proliferation. Role of a prostaglandin", cyclic AMP pathway and cross-talk with endothelin receptors, 1998, pp.273, 27300~27305
- Shi B, "Vascular endothelial growth factors and liver diseases", Hepatogastroenterology, 48, pp.1145~1148 (2001)
- Jaroszewicz J, "Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment", Cytokine, 44, pp.14~17 (2008)
- Aucejo F, "Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria", Liver Transpl, 15, pp.169~176 (2009)
- Perugorria MJ, "The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis", Hepatology, 48, pp.1251~1261 (2008)
- Mas VR, "Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation", Transplantation, 84, pp.1262~1271 (2007)
- Uematsu S, "Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma", J Gastroenterol Hepatol, 20, pp.583~588 (2005)
- Tu CT, "Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury", J Gastroenterol Hepatol, 22, pp.877~884 (2007)
- Toomey DP, "COX-2, VEGF and tumour angiogenesis", Surgeon, 7, pp.174~180 (2009)
- Tang TC, "Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma", World J Gastroenterol, 11, pp.1896~1902 (2005)
- Yoshida S, "COX-2", VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo, 2003, pp.83, 1385~1394
- Cao B, "Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice", World J Gastroenterol, 14, pp.6802~6807 (2008)
- 정승원, "Increased Expression of Cyclooxygenase-2 is Associated with the Progression to Cirrhosis", The Korean Journal of Internal Medicine, 25(4), pp.364~371 (2010), 대한내과학회